01 — At a Glance
The Chemistry Student Who Flunked The Lab Exam (But Promises To Study Harder)
- 52-Week High / Low₹492 / ₹211
- Q3 FY26 Revenue₹835 Cr
- Q3 FY26 PAT-₹119 Cr
- 9M FY26 Revenue₹2,968 Cr
- 9M FY26 PAT-₹234 Cr
- Book Value₹124
- Price to Book2.22x
- Dividend Yield0.00%
- Debt / Equity0.97x
- 1-Yr Return-38.2%
What Happened Here?: Chemplast delivered what management cheerfully calls “the most challenging quarter in the last 3 years.” Revenue ₹835 Cr (-21% YoY). Net loss ₹119 Cr. This is a chemicals company that specializes in PVC resins—products where China is literally dumping inventory at prices that make India’s best efforts look like charity. CRISIL downgraded outlook to Negative. Debt is ₹1,889 Cr. ROCE has collapsed to 1.83%. The open question: is this cycle bottom, or are we still falling?
02 — Introduction
Welcome to the Worst Year in a Decade (For This Particular Chemical Company)
Chemplast Sanmar (CSL) is not a household name. It should be, if you ever touched a PVC pipe, a cable, a hose, or any modern building material that needs polymer glueing. The company is the second-largest Suspension PVC manufacturer in India and the largest specialty paste PVC manufacturer domestically, with 66% market share. In normal years, this is a golden goose — 20%+ operating margins, 50%+ ROCE, bulletproof demand from irrigation, urban infra, and real estate sectors.
This is not a normal year.
In FY25, Chemplast reported operating margins of just 5% (down from 9% in FY23). In Q1 FY26, margins fell to 1.6%. In Q2 FY26, they bounced back slightly. In Q3 FY26 — the quarter we’re analyzing — operating margin turned negative at -7%. The company is literally losing money on every product it sells. Management’s official translation: “A perfect storm of adverse conditions for Suspension PVC plus continued weakness in Value-added Chemicals.” Translation of the translation: China dumped cheap PVC into India. The Indian government’s promised anti-dumping duty (ADD) turned into regulatory ping-pong. Monsoon disrupted shipping. Agrochemicals collapsed. And custom manufacturing chemicals (the growth bet) is taking longer to ramp than anyone budgeted.
The stock is down 38% in 12 months. CRISIL just revised the rating outlook to Negative. New MD takes charge April 2026. Debt has ballooned to ₹1,889 Cr. But in the latest concall (Feb 2026), management made a three-word claim that every investor is banking on: “cycle bottom confirmed.” Let’s separate thesis from hope.
Concall Insight (Feb 2026): Management stated Suspension PVC should be “at breakeven at PBT level by Feb-March” and that “January continuing into February” showed “an uptrend being visible.” China’s removal of export tax rebate on Suspension PVC (effective April 2026) was framed as a structural positive. This is management’s core inflection narrative.
03 — Business Model: They Make The Stuff That Holds Everything Together
Paste. Suspension. Chlor-Alkali. And A Bet On Custom Chemicals That’s Taking Longer Than A Monsoon.
Chemplast makes three main product categories. First, Suspension PVC (S-PVC) — 55% of consolidated revenue in Q3. This is the polymer used in rigid applications (pipes, profiles, roofing sheets) and flexible stuff (hoses, wires, cables). Demand comes from irrigation, urban infra, and real estate. The company’s subsidiary CCVL is the second-largest player in India with ~20% market share (on installed capacity basis).
Second, Specialty Paste PVC — 40% of consolidated revenue. This goes into footwear, auto upholstery, artificial leather, and flexible applications. CSL is the market leader with 83% of domestic production capacity and 66% market share. In normal cycles, this segment carries 20–25% margins. In Q3 FY26, it was running at full capacity but still posting losses due to import parity pricing pressure.
Third, Value-added Chemicals (13% of revenue) — caustic soda, hydrogen peroxide, chloromethanes, and refrigerant gases. These face global pricing pressure and are highly cyclical. CSL has captive power arrangements and integrated operations (salt mines, hydrogen production), but even backward integration can’t immunize you from China’s cost structure.
Then there’s Custom Manufactured Chemicals (CMCD) — the growth story. CSL is betting ₹1,600 Cr capex to build this into a ₹1,100–1,200 Cr revenue business by FY27-28 (delayed from earlier guidance). It supplies starting materials and advanced intermediates to pharma, agro, and fine chemical companies globally. Problem: agrochemical slowdown hit hard in 9M FY26. Product launches are slower than expected. This is a 20–25% margin opportunity but needs volume to matter.
S-PVC55%Consolid. Revenue
Specialty PVC32%Consolid. Revenue
Val. Chem.13%Consolid. Revenue
Market LeaderPaste PVC66% Share
The Real Problem: S-PVC is imported 60% by India (out of ~4 MT annual demand). China manufactures 20 MT annually and is exporting aggressively. In Q3, China’s export rebate was still 13% of export price (₹70–80 per MT), making China’s dumped prices unbeatable even for CSL’s integrated facilities. The Indian government promised anti-dumping duty in July–December 2024 (provisional), then issued final ADD in March 2025. But cheaper imports from Europe and Japan (excluded from the duty) kept flooding the market. Management framed this as “unfair trade practices,” which is technically correct but doesn’t pay the electricity bill.
💬 How much longer can an Indian chemicals company survive when a country with 10x manufacturing scale is dumping products at cost? This is the real question underlying Chemplast’s Q3 disaster.
04 — Financials Overview: The Numbers That Make Auditors Lose Sleep
Q3 FY26: The Quarter That Broke Everything
Result type: Quarterly Results (Q3) | 9M FY26 Revenue: ₹2,968 Cr | 9M FY26 PAT: -₹234 Cr
| Metric (₹ Cr) |
Q3 FY26
Dec 2025 |
Q3 FY25
Dec 2024 |
Q2 FY26
Sep 2025 |
YoY % |
QoQ % |
| Revenue | 835 | 1,058 | 1,033 | -21.0% | -19.1% |
| Operating Profit | -57 | 32 | 43 | NM | NM |
| OPM % | -7% | 3% | 4% | -1000 bps | -1100 bps |
| PAT | -119 | -49 | -51 | +144% | +133% |
| EPS (₹) | -7.54 | -3.09 | -3.23 | +144% | +133% |
The Ugly Truth: Operating profit went from +₹32 Cr in Q3 FY25 to -₹57 Cr in Q3 FY26. That’s an ₹89 Cr swing in one year. Revenue fell 21% YoY. Operating margin contracted from +3% to -7% (10 percentage point swing). PAT loss nearly tripled to -₹119 Cr. Management’s own words on the concall: “the most challenging quarter in the last 3 years.” Understatement of the fiscal year, honestly. This is what industrial commodity markets look like when global overcapacity meets regulatory uncertainty.
05 — Valuation: What’s It Worth When The Company Is Losing Money?
Fair Value Range — Educational Purpose Only
Method 1: Price-to-Book Based (When Earnings Are Negative)
Book Value = ₹124 per share. Price-to-Book = 2.22x. Historical median P/B for chemicals: 1.8x–2.5x. Adjusted for distress and debt: fair P/B = 1.2x–1.8x.
Range: ₹149 – ₹223
Method 2: EV/EBITDA (TTM Basis)
TTM EBITDA = ₹40 Cr (essentially near-zero). Enterprise Value = ₹5,652 Cr. EV/EBITDA = 141x (meaningless). Chemicals sector median = 8x–12x. If CSL recovers to ₹500 Cr EBITDA (pre-crisis level), fair EV at 9x = ₹4,500 Cr → Per share ₹287.
Normalized earnings scenario:
Range: ₹200 – ₹320
Method 3: DCF (Cycle Recovery Basis)
Base case: FCF improves to ₹100–150 Cr by FY28 (pending ADD implementation and cycle recovery). Terminal growth: 3%. WACC: 12% (higher for distress).
→ PV of 3-year recovery FCFs: ~₹250 Cr
→ Terminal Value (conservative): ~₹3,000 Cr
→ Total EV: ~₹3,250 Cr (including ₹1,889 Cr debt risk)
Range: ₹180 – ₹260
Fair Min: ₹150
CMP: ₹274 (At Premium)
Fair Max: ₹320
⚠️ EduInvesting Fair Value Range: ₹180 – ₹280. CMP ₹274 sits near the upper end of this range, pricing in a meaningful recovery assumption. This fair value range is for educational purposes only and is not investment advice. Please consult a SEBI-registered investment advisor before making any financial decision.
06 — What’s Cooking: The Regulatory Ping-Pong Match
Government Promises Anti-Dumping Duty. Government Changes Its Mind. Repeat.
